Advanced Non-small Cell Lung CancerPhase 1NCT06329895
A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants
A Phase 1 study testing BAY2927088, Dabigatran etexilate and Rosuvastatin in people with Advanced Non-small Cell Lung Cancer and EGFR Mutation, run by Bayer at 1 site in United Kingdom.
Trial summary
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) mutations. Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation
- What is being tested?
- BAY2927088, Dabigatran etexilate and Rosuvastatin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 25 Mar 2024to 10 Jun 2024
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Capable of giving signed informed consent as described in protocol which includes compliance with the requirements and restrictions listed in the informed consent form (ICF), and in this protocol.
- Participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent.
- Participants who are overtly healthy as determined by the investigator or medically qualified designee based on medical evaluation including medical history, laboratory tests, physical, and cardiac examination.
- Participant is a nonsmoker who has not used tobacco- or nicotine- containing products (e.g., nicotine patch) for at least 6 months before administration of the first study intervention.
- Body mass index (BMI) within the range 18.0 to 30 kg/m^2 (inclusive) at screening, with bodyweight above/equal to 50 kg.
- Female, of non-childbearing potential only
Show all 10Show fewer
- Females must not be pregnant or breastfeeding and must be documented as a woman of nonchildbearing potential. A negative pregnancy test is required.
- Male study participants of reproductive potential must agree to use adequate contraception when sexually active.
- From signing of the ICF until at least 3 months after the last dose of study intervention, and refrain from sperm donation during study intervention and for 6 months after the last dose of study intervention.
- Participant must be willing to comply with dietary and fluid requirements during the study period (including abstaining from alcohol use).
Who cannot join
- Existing relevant diseases of vital organs (e.g., liver diseases, heart diseases, gastrointestinal diseases, interstitial lung disease, renal diseases), central nervous system (for example seizures) or other organs (e.g., diabetes mellitus).
- Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination, and effects of the study intervention will not be normal.
- Febrile illness within 4 weeks prior to admission to the clinic.
- Any relevant diseases within 4 weeks prior to the first study intervention administration as judged by the investigator.
- A medical history of risk factors for Torsades de pointes (e.g., family history of long QT syndrome) or other clinically significant arrhythmias as judged by the investigator.
- Known severe allergies, allergies requiring therapy with corticosteroids, significant non-allergic drug reactions, or (multiple) drug allergies (excluding seasonal allergies such as non-severe hay fever that are asymptomatic and untreated during the time of study conduct).
Show all 10Show fewer
- Known history of hypersensitivity (or known allergic reaction) to BAY 2927088-related compounds, or any components of the formulation, dabigatran etexilate or rosuvastatin.
- History of known or suspected malignant tumors.
- Participants who in the investigator's judgment are perceived as having an increased risk of bleeding.
- Known or suspected coagulopathies.
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
PAREXEL International Early Phase Clinical Unit (London)
Harrow, HA1 3UJ
About this study
Official title: A Phase 1, Open Label, Fixed Sequence, Crossover Study to Investigate the Effect of BAY 2927088 on the Pharmacokinetics of Dabigatran Etexilate or Rosuvastatin in Healthy Participants
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) mutations.
Advanced NSCLC refers to a type of lung cancer that has spread from the lungs to nearby tissues or other body parts. People with advanced NSCLC may have changes in certain proteins, like EGFR and HER2, that cause uncontrolled cell growth and increased spread of cancer.
Read more
In this study, participants will be healthy and will not benefit from taking the study treatment, BAY2927088. However, the study will provide information about how to test BAY2927088 in future studies with people who have advanced NSCLC with EGFR or HER2 mutations.
BAY2927088 is under development for the treatment of advanced NSCLC with EGFR or HER2 mutations. It is expected to work against these changed proteins, which might slow down the spread of cancer.
Researchers think that BAY2927088 inhibits drug transporters such as P-gp (P-glycoprotein) and breast cancer resistance protein (BCRP). Drug transporters are proteins that help in the movement of certain drugs into, through, and out of the body's cells. Dabigatran is a drug used in the treatment of blood clots in a vein and rosuvastatin is a drug used in the treatment of high cholesterol in the blood.
The main purpose of this study is to find out how BAY2927088, taken as multiple doses, affects the levels of dabigatran and rosuvastatin in the blood of healthy participants. For this, researchers will measure the following for dabigatran and rosuvastatin, when given with and without BAY2927088:
- Area under the curve (AUC): a measure of the total amount of the drug in participants' blood over time
- Maximum observed concentration (Cmax): the highest amount of the drug in participants' blood
In this study, participants will take the following treatments:
- Dabigatran in the morning of Day 1 and 9.
- Rosuvastatin in the morning of Day 3 and 12.
- BAY2927088 two times a day in the morning and evening of Days 6 to 15.
Participants will be in this study for about 8 weeks with 3 visits to the study clinic.
Participants will visit the study clinic:
- at least once, 2 to 28 days before the treatment starts, to confirm they can take part in this study
- once on the day before the treatment starts and will stay in the clinic until Day 16 of the treatment
- once, 7 to 10 days after last dose of BAY2927088, for a health check-up
During the study, the doctors and their study team will:
- do physical examinations
- collect blood samples from the participants to measure the levels of dabigatran, rosuvastatin and of BAY2927088
- check participants' health by performing tests such as blood and urine tests, and checking heart health using an electrocardiogram (ECG)
- ask the participants questions about how they are feeling and what adverse events they are having
An adverse event is any medical problem that a participant has during a study. The study doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.
- Being tested
- BAY2927088, Dabigatran etexilate, Rosuvastatin
- Keywords
- HER2, EGFR, NSCLC
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BAY2927088Drug
Oral administration.
Dabigatran etexilateDrug
Oral administration.
RosuvastatinDrug
Oral administration.
| Study group | Role | What they receive |
|---|---|---|
| Healthy volunteers | Experimental | The healthy volunteers will be confined to the clinic throughout the Intervention Period of the study.
The study includes visits during Screening, Intervention, and Follow-up. Receives: Drug: BAY2927088; Drug: Dabigatran etexilate; Drug: Rosuvastatin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cmax of unconjugated dabigatran when given with and without BAY2927088
Cmax: Maximum observed drug concentration
Measured: Pre-dose on Day 1 and 9, multiple post-dose time points on Day 1-2 and Day 9-11 and one time point on Day 3 and Day 12
AUC of unconjugated dabigatran when given with and without BAY2927088
AUC: Area under the concentration vs time curve
Measured: Pre-dose on Day 1 and 9, multiple post-dose time points on Day 1-2 and Day 9-11 and one time point on Day 3 and Day 12
Cmax of rosuvastatin when given with and without BAY2927088
Measured: Pre-dose on Day 3, Day 12, multiple timepoints on Day 3-5, Day 12-15, one timepoint on Day 6 and Day 16
AUC of rosuvastatin when given with and without BAY2927088
Measured: Pre-dose on Day 3, Day 12, multiple timepoints on Day 3-5, Day 12-15, one timepoint on Day 6 and Day 16
Secondary outcomes (2)
Number of participants with treatment-emergent adverse events (TEAEs)
Measured: Up to 7 days after the last administration of study intervention
Severity of TEAEs
Measured: Up to 7 days after the last administration of study intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Mar 2024
- Study start25 Mar 2024
- Primary completion10 Jun 2024
- Study completion10 Jun 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Advanced Non-small Cell Lung CancerStudies of the same condition, open and under way.
- More trials run by BayerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- Bayer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06329895
- Sponsor's protocol ID
- 22252
- Status last verified
- Jun 2024
- First submitted
- 19 Mar 2024
- Last updated
- 5 Jul 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Study at a glance
From the registry record, last updated by the sponsor on 5 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1, Open Label, Fixed Sequence, Crossover Study to Investigate the Effect of BAY 2927088 on the Pharmacokinetics of Dabigatran Etexilate or Rosuvastatin in Healthy Participants
- ClinicalTrials.gov ID
- NCT06329895
- Acronym / sponsor ID
- 22252
- Keywords
- HER2, EGFR, NSCLC
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 15 participants (actual)
- Lead sponsor
- BayerIndustry (pharma, biotech, devices)
- Study start
- 25 Mar 2024 (actual)
- Primary completion
- 10 Jun 2024 (actual)
- Study completion
- 10 Jun 2024 (actual)
- First posted
- 26 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) mutations.
Advanced NSCLC refers to a type of lung cancer that has spread from the lungs to nearby tissues or other body parts. People with advanced NSCLC may have changes in certain proteins, like EGFR and HER2, that cause uncontrolled cell growth and increased spread of cancer.
In this study, participants will be healthy and will not benefit from taking the study treatment, BAY2927088. However, the study will provide information about how to test BAY2927088 in future studies with people who have advanced NSCLC with EGFR or HER2 mutations.
BAY2927088 is under development for the treatment of advanced NSCLC with EGFR or HER2 mutations. It is expected to work against these changed proteins, which might slow down the spread of cancer.
Researchers think that BAY2927088 inhibits drug transporters such as P-gp (P-glycoprotein) and breast cancer resistance protein (BCRP). Drug transporters are proteins that help in the movement of certain drugs into, through, and out of the body's cells. Dabigatran is a drug used in the treatment of blood clots in a vein and rosuvastatin is a drug used in the treatment of high cholesterol in the blood.
The main purpose of this study is to find out how BAY2927088, taken as multiple doses, affects the levels of dabigatran and rosuvastatin in the blood of healthy participants. For this, researchers will measure the following for dabigatran and rosuvastatin, when given with and without BAY2927088:
- Area under the curve (AUC): a measure of the total amount of the drug in participants' blood over time
- Maximum observed concentration (Cmax): the highest amount of the drug in participants' blood
In this study, participants will take the following treatments:
- Dabigatran in the morning of Day 1 and 9.
- Rosuvastatin in the morning of Day 3 and 12.
- BAY2927088 two times a day in the morning and evening of Days 6 to 15.
Participants will be in this study for about 8 weeks with 3 visits to the study clinic.
Participants will visit the study clinic:
- at least once, 2 to 28 days before the treatment starts, to confirm they can take part in this study
- once on the day before the treatment starts and will stay in the clinic until Day 16 of the treatment
- once, 7 to 10 days after last dose of BAY2927088, for a health check-up
During the study, the doctors and their study team will:
- do physical examinations
- collect blood samples from the participants to measure the levels of dabigatran, rosuvastatin and of BAY2927088
- check participants' health by performing tests such as blood and urine tests, and checking heart health using an electrocardiogram (ECG)
- ask the participants questions about how they are feeling and what adverse events they are having
An adverse event is any medical problem that a participant has during a study. The study doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Healthy volunteers | Experimental | Drug: BAY2927088, Drug: Dabigatran etexilate, Drug: RosuvastatinThe healthy volunteers will be confined to the clinic throughout the Intervention Period of the study. The study includes visits during Screening, Intervention, and Follow-up. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (10 listed)
- Capable of giving signed informed consent as described in protocol which includes compliance with the requirements and restrictions listed in the informed consent form (ICF), and in this protocol.
- Participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent.
- Participants who are overtly healthy as determined by the investigator or medically qualified designee based on medical evaluation including medical history, laboratory tests, physical, and cardiac examination.
- Participant is a nonsmoker who has not used tobacco- or nicotine- containing products (e.g., nicotine patch) for at least 6 months before administration of the first study intervention.
- Body mass index (BMI) within the range 18.0 to 30 kg/m^2 (inclusive) at screening, with bodyweight above/equal to 50 kg.
Key exclusion criteria (10 listed)
- Existing relevant diseases of vital organs (e.g., liver diseases, heart diseases, gastrointestinal diseases, interstitial lung disease, renal diseases), central nervous system (for example seizures) or other organs (e.g., diabetes mellitus).
- Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination, and effects of the study intervention will not be normal.
- Febrile illness within 4 weeks prior to admission to the clinic.
- Any relevant diseases within 4 weeks prior to the first study intervention administration as judged by the investigator.
- A medical history of risk factors for Torsades de pointes (e.g., family history of long QT syndrome) or other clinically significant arrhythmias as judged by the investigator.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BAY2927088Oral administration. | Drug | Healthy volunteers |
| Dabigatran etexilateOral administration. | Drug | Healthy volunteers |
| RosuvastatinOral administration. | Drug | Healthy volunteers |
Primary outcome
Cmax of unconjugated dabigatran when given with and without BAY2927088
Time frame: Pre-dose on Day 1 and 9, multiple post-dose time points on Day 1-2 and Day 9-11 and one time point on Day 3 and Day 12
Cmax: Maximum observed drug concentration
AUC of unconjugated dabigatran when given with and without BAY2927088
Time frame: Pre-dose on Day 1 and 9, multiple post-dose time points on Day 1-2 and Day 9-11 and one time point on Day 3 and Day 12
AUC: Area under the concentration vs time curve
Cmax of rosuvastatin when given with and without BAY2927088
Time frame: Pre-dose on Day 3, Day 12, multiple timepoints on Day 3-5, Day 12-15, one timepoint on Day 6 and Day 16
AUC of rosuvastatin when given with and without BAY2927088
Time frame: Pre-dose on Day 3, Day 12, multiple timepoints on Day 3-5, Day 12-15, one timepoint on Day 6 and Day 16
2 secondary outcomes
Number of participants with treatment-emergent adverse events (TEAEs)
Time frame: Up to 7 days after the last administration of study intervention
Severity of TEAEs
Time frame: Up to 7 days after the last administration of study intervention
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jul 2024.
- Individual participant dataSharing planned: No. Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Related trials for Advanced Non-small Cell Lung Cancer
RecruitingPhase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Active, not recruitingPhase 3
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8
RecruitingPhase 3
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Non-small Cell Lung Cancer
RecruitingPhase 1
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
RecruitingPhase 1/2
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing BAY2927088, Dabigatran etexilate and Rosuvastatin in people with Advanced Non-small Cell Lung Cancer and EGFR Mutation, run by Bayer at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cmax of unconjugated dabigatran when given with and without BAY2927088 (time frame: Pre-dose on Day 1 and 9, multiple post-dose time points on Day 1-2 and Day 9-11 and one time point on Day 3 and Day 12). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jul 2024.